Amylyx Pharmaceuticals, Inc.
32.40USD
-1.4800 (-4.37%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 22.2M | 380.8M | 87.4M | 0.0 | 0.0 | 28.2M |
| Q1 | — | 71.4M | 88.6M | 0.0 | — | — |
| Q2 | — | 98.2M | -1.0M | 0.0 | — | — |
| Q3 | 345.0K | 102.7M | 416.0K | 0.0 | 37.8K | — |
| Q4 | 21.9M* | 108.4M* | -665.0K* | 0.0* | -37.8K | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -3.39 | .700 | -4.43 | -1.53 | -1.50 | -1.15 |
| Q1 | -.930 | .020 | -1.75 | -.420 | -.370 | — |
| Q2 | -.930 | .310 | -1.07 | -.460 | -.390 | — |
| Q3 | -.920 | .300 | -1.07 | -.370 | -.375 | — |
| Q4 | -.730* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .068* |
| -.551* |
| -.349* |
| -.366 |
| — |